Comparative Pharmacology
Head-to-head clinical analysis: DURACILLIN A S versus PIPERACILLIN TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURACILLIN A S versus PIPERACILLIN TAZOBACTAM.
DURACILLIN A.S. vs Piperacillin-Tazobactam
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G procaine is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
600,000 units intramuscularly once daily; or 1.2 million units intramuscularly every 12 hours for severe infections.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Primarily renal (60-90% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal elimination (<10%)
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic + Beta-Lactamase Inhibitor